Fintel reports that on November 13, 2024, Canaccord Genuity downgraded their outlook for Doximity (NYSE:DOCS) from Buy to ...

Fintel reports that on November 13, 2024, Canaccord Genuity upgraded their outlook for Viant Technology (NasdaqGS:DSP) from ...

ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness ...

Canaccord Genuity Group Inc. recorded strong growth in wealth-management and capital-markets divisions for its fiscal second ...

Canaccord Genuity Group (TSE:CF – Get Free Report) had its price target increased by investment analysts at Ventum Financial from C$10.25 to C$12.00 in a report issued on Monday,BayStreet.CA reports.

Firm-wide Revenue: $128 million for the quarter, up 27% year-over-year. Fiscal Year-to-Date Revenue: $857 million, up 26% ...

Analysts at Canaccord Genuity lowered their target price on shipbroking services business Braemar from 410.0p to 380.0p on ...

Stantec (TSE:STN – Get Free Report) (NYSE:STN) had its price target hoisted by stock analysts at Canaccord Genuity Group from ...

Good morning, ladies and gentlemen. Thank you for standing by. I'd like to welcome everyone to the Canaccord Genuity Group Inc. Fiscal 2025 Second Quarter Results Conference Call. All lines have been ...

Canaccord Genuity Group Inc (TSX:CF) is set to release its Q2 2025 earnings on Nov 7, 2024. The consensus estimate for Q2 2025 revenue is $0.43 million, and the earnings are expected to come in at $0.

About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of ...